|

Saroglitazar Magnesium 1 mg Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Not any, Subjects will be domicile in clinic from Day -1 till Day 5 or Day 7 and from Day 27 through day 29 for PK sampling procedures.

Pipeline

Phase 1: 2Phase 3: 1

Top Sponsors

  • Zydus Therapeutics Inc.3

Indications

  • Liver Disease3
  • Cholestatic Liver Disease2
  • Primary Biliary Cholangitis1
  • Hepatic Impairment1
  • Cirrhosis1

Indianapolis, Indiana2 trials

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

Zydus Site US001

Phase 1
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Zydus US002

Phase 1

Los Angeles, California1 trial

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Zydus US013

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.